Pfizer's once-daily Lyrica trial fails to meet goal
Nov 16 (Reuters) - Pfizer Inc said on Friday a late-stage trial of a once-a-day formulation of its drug pregabalin did not significantly reduce the frequency of some types of seizures in patients with epilepsy.
The drug, sold under the brand name Lyrica, is currently used to treat epilepsy when given several times a day in combination with other drugs.
Pfizer said the lack of a statistically significant improvement may have been due to a higher-than-expected response among patients taking the placebo.
The trial was the first of three trials testing the drug as a once-a-day therapy. The company is also testing it in patients with fibromyalgia and some types of nerve pain, for which it is also approved in its immediate-release formulation.
- Obama and Castro shake hands, Zuma humiliated at Mandela memorial |
- Google bus blocked in San Francisco gentrification protest
- Reporter can keep sources secret in Colorado theater shooting: court
- Couple, four children missing in Nevada found safe in canyon
- Regulators seek to curb Wall St. trades with Volcker rule |